EXTRANODAL NK/T-CELL LYMPHOMA
Clinical trials for EXTRANODAL NK/T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new EXTRANODAL NK/T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for EXTRANODAL NK/T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on rare blood cancer shows promise in early trial
Disease control Recruiting nowThis study tests two drugs, tislelizumab and zeprumetostat, together in people with a rare type of lymphoma that has come back or not responded to treatment. About 107 adults will take part to see if the combination is safe and shrinks tumors. The goal is to control the cancer, n…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for deadly lymphoma combo: drug cocktail targets both cancer and immune chaos
Disease control Recruiting nowThis trial tests a new combination of drugs (MEPL-G) for people with a rare and aggressive lymphoma (NK/T-cell) that has triggered a life-threatening immune overreaction called HLH. The goal is to control both the cancer and the dangerous inflammation quickly. About 25 adults wil…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New pill shows early promise against tough cancers
Disease control Recruiting nowThis early-stage study is testing a new oral drug called CS23546 in about 156 adults with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Resear…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for rare blood cancer: platform trial tests multiple drugs at once
Disease control Recruiting nowThis study is testing three oral drugs—roginolisib, golcadomide, and azacitidine—alone or in combination for people with peripheral T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: Phase 1 finds safe doses, and Phase 2 checks if the drug…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC